Atyr Pharma Inc. (LIFE)

Trade LIFE now with
12/21/2020 7:19:17 AM ATyr Pharma Completes Enrollment In Phase 1b/2a Clinical Trial Of ATYR1923 In Pulmonary Sarcoidosis; Sees Data In Q3
9/14/2020 8:20:25 AM ATyr Plans Sale Of Up To $20 Mln Of Common Stock To Aspire Capital Fund, LLC
8/11/2020 7:19:22 AM ATyr Pharma Partner Kyorin Proceeds To Phase 1 Trial Of ATYR1923 In Japan
6/15/2020 7:15:46 AM ATyr Pharma Doses First Patient In Phase 2 Study Evaluating ATYR1923, In COVID-19 Patients
4/21/2020 8:39:44 AM ATyr: FDA Accepts IND Application On ATYR1923 In Phase 2 Study For COVID-19
3/17/2020 8:42:23 AM ATyr Pharma Appoints Arthur Mercurio As A Scientific Advisor
2/6/2020 9:08:27 AM ATyr Pharma Reports Pricing Of $18 Mln Public Offering
1/6/2020 8:23:53 AM ATyr Pharma Enters Collaboration And License Agreement With Kyorin
7/1/2019 8:11:04 AM ATyr Pharma Appoints Jane Gross And Svetlana Lucas To Board
12/4/2018 8:15:12 AM ATyr Pharma Announces Initiation Of Phase 1b/2a Study Of ATYR1923
7/31/2018 8:05:22 AM ATyr Pharma Names Jill Broadfoot CFO
7/26/2018 8:21:12 AM ATyr Pharma Presents Positive Lung And Skin Findings With ATYR1923 In A Translational Animal Model
5/17/2018 7:34:03 AM ATyr Pharma Presents Poster On Preclinical Data From ATYR1923 Program